Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma
Information source: National Cancer Institute (NCI)
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Lymphoma
Intervention: bleomycin sulfate (Biological); filgrastim (Biological); rituximab (Biological); cyclophosphamide (Drug); cytarabine (Drug); doxorubicin hydrochloride (Drug); etoposide phosphate (Drug); ifosfamide (Drug); methotrexate (Drug); prednisolone (Drug); prednisone (Drug); vincristine sulfate (Drug); vindesine (Drug)
Sponsored by: University Hospital Southampton NHS Foundation Trust.
Official(s) and/or principal investigator(s):
Peter Johnson, MD, Principal Investigator, Affiliation: University Hospital Southampton NHS Foundation Trust.
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies,
such as rituximab, can block cancer growth in different ways. Some block the ability of
cancer cells to grow and spread. Others find cancer cells and help kill them or carry
cancer-killing substances to them. Giving rituximab together with one of five different
combination chemotherapy regimens may kill more cancer cells.
PURPOSE: This clinical trial is studying giving rituximab together with combination
chemotherapy to see how well it works in treating patients with primary mediastinal diffuse
large B-cell lymphoma.
Official title: A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma (IELSG 26)
Study design: Allocation: Non-Randomized, Primary Purpose: Treatment
Primary outcome: Complete response rate on PET scanning at the completion of chemoimmunotherapy
- To systematically analyze the phenotype and molecular characteristics in patients with
primary mediastinal diffuse large B-cell lymphoma.
- To determine the PET response rate following chemoimmunotherapy in these patients.
- To obtain data, on a nonrandomized basis, regarding the outcomes of treatment using
different chemoimmunotherapy regimens and using or omitting mediastinal radiotherapy,
depending upon the practice of the participating institutions.
- To analyze progression-free and overall survival in patients treated with these
OUTLINE: This is a multicenter study.
Patients receive any one of the following standard chemoimmunotherapy regimens.
- Cohort 1 (R-CHOP-21): Patients receive rituximab IV, cyclophosphamide IV, doxorubicin
hydrochloride IV, and vincristine IV on day 1 and oral prednisolone on days 1-5.
Treatment repeats every 21 days in the absence of disease progression or unacceptable
- Cohort 2 (R-CHOP-14): Patients receive rituximab IV, cyclophosphamide IV, doxorubicin
hydrochloride IV, and vincristine IV on day 1, oral prednisolone on days 1-5, and
filgrastim (G-CSF) subcutaneously (SC) on days 5-12. Treatment repeats every 14 days in
the absence of disease progression or unacceptable toxicity.
- Cohort 3 (R-MACOP-B): Patients receive rituximab IV on days 1, 22, 43, 64, 85, and 106;
cyclophosphamide IV and doxorubicin hydrochloride IV on days 1, 15, 29, 43, 57, and 71;
methotrexate IV on days 8, 36, and 64; vincristine IV on days 8, 22, 36, 50 ,64, and
78; bleomycin IV on days 22, 50, and 78; and oral prednisolone on days 1-84, followed
by a taper.
- Cohort 4 (R-VACOP-B): Patients receive rituximab IV on days 1, 22, 43, 64, 85, and 106;
cyclophosphamide IV on days 1, 29, and 57; doxorubicin hydrochloride IV on days 1, 15,
29, 43, 57, and 71; etoposide phosphate IV on days 15, 16, 43, 44, 71, and 72;
vincristine IV and bleomycin IV on days 8, 22, 36, 50, 64, and 78; and oral
prednisolone on days 1-84, followed by a taper.
- Cohort 5 (R-ACVBP): Patients receive rituximab IV, doxorubicin hydrochloride IV, and
cyclophosphamide IV on day 1; vindesine IV and bleomycin IV on days 1 and 5; oral
prednisone on days 1-5; methotrexate intrathecally on day 2; and G-CSF SC on days 6-13
for 4 courses in the absence of disease progression or unacceptable toxicity. After
completion of 4 courses of R-ACVBP, patients receive consolidation therapy comprising
high-dose methotrexate IV, rituximab IV, ifosfamide IV, etoposide phosphate IV, and
cytarabine SC according to protocol GELA LNH03-2B.
Patients with an International Prognostic Index score of 4 or greater or disease in close
proximity to the spinal cord or cerebral meninges may receive prophylactic treatment to the
CNS according to local protocol.
Beginning 8 weeks after completion of chemoimmunotherapy, patients undergo radiotherapy to
the original tumor volume according to local protocol.
Fresh or fixed tissue from prior biopsy is obtained if possible. Samples are analyzed for
CD3, CD20, CD30, CD15, CD10, Bcl-6, Bcl-2, MAL protein (if available), and Ki-67 via
After completion of study treatment, patients are followed periodically.
Minimum age: 18 Years.
Maximum age: N/A.
- Histologically confirmed primary mediastinal diffuse large B-cell lymphoma
- CD20-positive disease
- Any stage of disease
- Must have a dominant mass within the anterior mediastinum
- ANC ≥ 1. 5 x 10^9/L (unless due to lymphoma)
- Platelets ≥ 100 x 10^9/L (unless due to lymphoma)
- WBC ≥ 3. 0 x 10^9/L (unless due to lymphoma)
- Serum creatinine ≤ 2 times upper limit of normal (ULN) (unless due to lymphoma)
- AST/ALT ≤ 2. 5 times ULN (unless due to lymphoma)
- Total bilirubin ≤ 2. 5 times ULN (unless due to lymphoma)
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Must be fit to receive chemotherapy with curative intent
- No evidence of clinically significant cardiac disease* within the past 12 months,
including any of the following:
- Symptomatic ventricular arrhythmias
- Congestive heart failure
- Myocardial infarction NOTE: * Cardiac compromise due to local extension of
lymphoma will not be an exclusion criterion in the absence of other cardiac
- No known HIV infection
- No psychological, familial, sociological, or geographical condition potentially
hampering compliance with the study protocol and follow-up schedule
- Able and willing to give informed consent and to undergo staging, including PET
PRIOR CONCURRENT THERAPY:
- No prior treatment for lymphoma
- Prior corticosteroids for up to 1 week allowed for the relief of local compressive
Locations and Contacts
Saint Bartholomew's Hospital, London, United Kingdom; Recruiting
Contact Person, Phone: 44-207-796-3979, Email: firstname.lastname@example.org
Leeds Cancer Centre at St. James's University Hospital, Leeds, England LS9 7TF, United Kingdom; Recruiting
Contact Person, Phone: 44-113-206-6400
St. George's Hospital, London, England SW17 0QT, United Kingdom; Recruiting
Contact Person, Phone: 44-208-725-2425, Email: email@example.com
Christie Hospital, Manchester, England M20 4BX, United Kingdom; Recruiting
Contact Person, Phone: 44-845-226-3000
Mount Vernon Cancer Centre at Mount Vernon Hospital, Northwood, England HA6 2RN, United Kingdom; Recruiting
Contact Person, Phone: 44-1923-826-111
Cancer Research Centre at Weston Park Hospital, Sheffield, England S1O 2SJ, United Kingdom; Recruiting
Contact Person, Phone: 44-114-226-5007, Email: firstname.lastname@example.org
Southampton General Hospital, Southampton, England SO16 6YD, United Kingdom; Recruiting
Contact Person, Phone: 44-238-079-6186, Email: email@example.com
Royal Marsden - Surrey, Sutton, England SM2 5PT, United Kingdom; Recruiting
Contact Person, Phone: 44-208-661-3279, Email: firstname.lastname@example.org
Clinical trial summary from the National Cancer Institute's PDQ® database
Starting date: June 2007
Last updated: July 7, 2009